



Cite this: *Lab Chip*, 2022, 22, 463

On-chip miRNA extraction platforms: recent technological advances and implications for next generation point-of-care nucleic acid tests

Loukia Petrou  and Sylvain Ladame *

Circulating microRNAs (or miRNAs) in bodily fluids, are increasingly being highlighted as promising diagnostic and predictive biomarkers for a broad range of pathologies. Although nucleic acid sensors have been developed that can detect minute concentrations of biomarkers with high sensitivity and sequence specificity, their robustness is often compromised by sample collection and processing prior to analysis. Such steps either (i) involve complex, multi-step procedures and toxic chemicals unsuitable for incorporation into portable devices or (ii) are inefficient and non-standardised therefore affecting the reliability/reproducibility of the test. The development of point-of-care nucleic acid tests based on the detection of miRNAs is therefore highly dependent on the development of an automated, on-chip, sample processing platform that would enable extraction or pre-purification of the biological specimen prior to reaching the sensing platform. In this review we categorise and critically discuss the most promising technologies that have been developed to facilitate the transition of nucleic acid tests based on miRNA detection from bench to bedside.

Received 26th September 2021,
Accepted 4th November 2021

DOI: 10.1039/d1lc00868d

rsc.li/loc

Introduction

miRNAs as biomarkers

Circulating microRNAs (miRNAs) are short (19–22 bp), non-coding nucleic acids that have recently emerged as promising biomarkers for a variety of diseases including cancer (for both diagnosis and origin identification) as well as heart diseases, neurological and infectious diseases.^{1–3}

The biogenesis of miRNAs starts in the nucleus where following DNA transcription, the stem-loop precursor pri-miRNAs are cleaved to form pre-miRNAs which are then transported out of the nucleus through exportins.⁴ In the cytoplasm, the pri-miRNAs are cleaved into miRNA duplexes with the active strand binding to Argonaute proteins and the inactive strand being degraded.⁵ The association with Argonaute proteins allows the miRNAs to bind to mRNA and silence its translation into proteins either through degradation or ribosome stalling.^{6–8} miRNAs thus play an important role in post-transcriptional gene regulation and recently have also been identified as mediators for cell-to-cell communication as certain miRNAs are preferentially sorted into exosomes.^{9,10}

The isolation of these biomarkers from bodily fluids poses unique impediments. They circulate mainly using the two main transport mechanisms mentioned previously which

protect them from degradation while in circulation. Because of this they have enhanced stability in circulation which is however compromised as soon as they are released due to their exposure to endogenous ribonucleases (RNases) which has also been previously demonstrated when injecting synthetic miRNAs or miRNAs purified from plasma back into unprocessed plasma. This led to their rapid degradation highlighting their instability when extracted from their protective transporters.¹¹ They are still more stable than longer RNAs such as mRNAs when exposed to RNases which further highlights their utility as biomarkers.¹² Promising point-of-care (POC) techniques of nucleic acid isolation have been summarised previously.^{13–15} Given the emerging evidence of the clinical value of miRNAs as diagnostic or prognostic biomarkers, we will focus exclusively in this review on this specific class of molecular biomarkers and recent progress made towards their isolation from clinical samples. Fig. 1 summarises the workflow of the techniques discussed in this review to illustrate the types of samples used and how these are processed. This review will focus primarily on sample processing rather than sensing, although selected technologies that successfully combined miRNA extraction and detection will also be discussed.

Liquid biopsies and miRNAs

Biomarkers are clinically useful in a multitude of scenarios: diagnosis, prognosis, monitoring, screening, and treatment of diseases. Liquid biopsies allow minimally or non-invasive

Department of Bioengineering, Imperial College London, London, W12 0BZ, UK.
E-mail: s.ladame@imperial.ac.uk





Fig. 1 miRNAs and different locations from which they can be isolated showing any additional steps required in the extraction process.

access to important biomarkers and provide valuable alternatives to more invasive tissue biopsies.¹⁶ This involves sampling of bodily fluids (most commonly blood, saliva, urine or interstitial fluid) and can avoid complications arising from traditional tissue biopsies. Liquid biopsies can also delineate the path to diagnosis when samples are not easily accessible.¹⁷ For example, this is particularly relevant in diseases such as Alzheimer's disease or metastatic cancer lesions.^{18,19} Wide-spread usage of liquid biopsies in clinical settings is often limited by the sample processing required for test result attainment.

Despite some clustering observed when analysing miRNAs from a variety of bodily fluids, their relative and absolute concentrations may vary with urine and saliva yielding a smaller number of miRNAs than blood or plasma.²⁰ Weber *et al.* looked at the miRNA expression in 12 different bodily fluids and found that saliva had the highest numbers of unique detectable miRNAs and while some abundant miRNAs can be identified across a variety of bodily fluids, some are enriched in certain types of samples.²¹ This has also been shown in forensic analysis that identified certain miRNA patterns to assist in identification of the source of a bodily fluid.²² It is notable however that differences exist in the miRNA concentration between samples of similar origin such as serum and plasma from the same individual. This could be explained by the association of miRNAs with platelets that are lost in the coagulation process to obtain serum but exact causes remain largely unclear, underlining the source of error blood sample processing represents on the miRNA profile obtained.²³ The complexity involved in sample processing and miRNA sensing has been highlighted previously. The transporting mechanism of miRNAs (*i.e.* how many are within vesicles, bound to proteins or freely circulating) for each liquid biopsy remains elusive. Arroyo *et al.* looked into the transport mechanism in plasma and serum and determined that the main mechanism is Argonaute2 (Ago2) proteins with only a fewer proportion of miRNAs found in vesicles.²⁴ Turchinovich *et al.* looked into the transport of miRNAs in plasma and cell culture media

and agreed that extracellular miRNAs are primarily transported bound to Ago2.²⁵ This however was contradicted by the findings of Gallo *et al.* who determined that most miRNAs in serum and saliva are actually found within exosomes.²⁶ These studies highlight not only the complexity of the field but also the discrepancy in the literature due at least in part to the lack of standardised protocols and technologies for sample processing, miRNA extraction as well as detection.

Herein, we discuss a variety of techniques used for miRNA extraction and their incorporation into POC devices for down-stream detection. We highlight some emerging technologies and separate them into a) those that are carried out entirely off-chip, b) those that involve some off-chip processing, and c) those that have achieved on-chip miRNA isolation and sensing in a processing-free manner (or involving minimal processing) and hold the most promise for translation into clinical settings as POC devices.

Off-chip miRNA extraction

Nucleic acid extraction

Background. For nucleic acid extraction to be possible, nucleic acids first need to be released from their enclosure or carrier. At the same time, the nucleases that could lead to degradation of the sample (ribonucleases such as RNases or DNases) need to be deactivated. Finally, the nucleic acid needs to be isolated from the often-complex mixture of biomolecules and biometabolites.

There are also obvious differences stemming from where miRNAs are isolated from which bring about differences in protocols. As described by Pritchard *et al.*, the yield is higher from cell lysates or tissues compared to bodily fluids and the extracted miRNAs are typically of higher quality.²⁷ Bodily fluids pose an additional challenge due to the inherent RNase activity which could degrade any extracted miRNAs if the RNases are not deactivated at the same time. Since the isolation process involves the same main steps, we will be including kits that successfully carried out miRNA isolation from cells in this review as such protocols are amendable to miRNA extraction from other sources following optimisation. Although the methodology for isolating miRNA is mostly similar to that for isolating other RNA species (*e.g.* mRNA or lncRNA), miRNA isolation involves specific enrichment of smaller RNAs.²⁸ This can be achieved through gel-purification, but more recent methods harnessed by kits involve column-based techniques.

Chemical miRNA isolation. One of the most common ways of isolating miRNAs is the phenol-chloroform phase extraction. This involves mixing of phenol and chloroform with the sample and centrifuging it. The phenol-chloroform leads to denaturation of the proteins and chaotropic salts are often also used to assist in this process. The proteins following centrifugation remain in the lower, organic phase while the nucleic acids are found in the upper, aqueous phase which can be extracted for further processing or



purification.²⁹ Given the multiple steps required as well as toxic reagents, this is not suitable for use at the POC where multiple samples need to be analysed safely and quickly.

Column-based miRNA isolation. This method most commonly involves silica-based columns. This takes advantage of the interaction between the nucleic acids (in this case miRNAs) and the silica particles. After the miRNAs have been extracted into the aqueous phase, the addition of ethanol increases their affinity to the beads through intermolecular electrostatic forces, dehydration and intermolecular hydrogen bonding.³⁰ The organic phase is then separated by centrifugation, leaving the nucleic acids bound onto the solid phase which is then eluted.

miRNA extraction kits

Recent efforts to allow faster and more efficient nucleic acid extraction have been streamlined by commercially available extraction kits. Longer RNAs or DNAs compared to miRNAs, defer in both increased length and stability and are thus generally easier to handle. This has led to the development of kits specifically targeting miRNA extraction, through

incorporating additional steps to ensure adequate recovery of short RNAs. For example, the Ambion PureLink miRNA isolation kit encompasses a double column isolation method, whereby the first column is used to selectively bind larger RNA fractions while the miRNAs pass into the flow-through and are then purified by the second column. Separation by size is particularly important in samples where there is a mix of nucleic acid types. For example, serum and plasma contain mainly small RNAs and therefore do not necessitate targeted extraction of smaller RNAs.³¹ Some commonly used kits for a variety of samples including plasma/serum, urine, cerebrospinal fluid (CSF) and cell lysates are summarised in Table 1.

The use of toxic reagents such as phenol and chloroform for extraction, necessitates careful handling by trained personnel in a lab-based facility and thus limits translation into a POC device. The same applies to centrifugations which are a recurrent key step in most commercial kits and prevent direct implementation into a POC device. Recent attempts have been made to develop kits with no such chemical extraction requirements, but similar extraction capacities that are included in Table 1.

Table 1 Summary of commonly used miRNA extraction kits for a variety of sample types

Name of kit	Phenol/chloroform extraction	Type of miRNA purification	Type of sample	Amount of sample required	Steps on protocol	Time required ^a	Cost per sample ^b
miRNeasy serum/plasma kit (QIAGEN)	Yes	Chemical and column-based	Serum/plasma	200 µL	15 steps	40 min	£8.0
miRNeasy serum/plasma advanced kit (QIAGEN)	No	Column-based	Serum/plasma	200 µL	12 steps	25 min	£6.0
Ambion® PureLink™ miRNA isolation kit (Invitrogen)	No – chloroform is optional for larger tissue amounts	Column-based	Cells	<10 ⁶ cells <5 mg tissue	24 steps	20 min	£8.4
MagMAX mirVana total RNA isolation kit (Applied Biosystems)	No – chloroform is optional	Magnetic beads	Blood Tissue Plasma/serum Urine	50 µL 50 mg 100 µL 250 µL	17 steps 12 steps 17 steps 13 steps	90–120 min	£4.3
TaqMan™ miRNA ABC purification kit (ThermoFisher scientific)	No	Magnetic beads	Blood Plasma/serum Cells	10 µL 50 µL 10–10 ⁶ cells	23 steps 22 steps 22 steps	75 min	£10.8
mirPremier microRNA isolation kit (Sigma-Aldrich)	No	Column-based	Saliva Urine Cells	50 µL 50 µL 0.1–7 × 10 ⁶ cells	23 steps 23 steps 13 steps	30 min	£5.4
Total RNA purification kit (Norgen Biotek)	No	Column-based	Blood	100 µL	14 steps	15 min	Not available
Exosome miRNA extraction kits							
miRCURY exosome kit (QIAGEN)	No	Column-based	Plasma/serum	500–1400 µL	8–11 steps	100 min	£6–£16;
			Urine/cells/cerebrospinal fluid	1–10 mL	8 steps		£2.4–24
exoRNeasy serum–plasma Midi kit (QIAGEN)	Yes	Column-based	Plasma/serum	0.1–1 mL	19 steps	60 min	£18.2

^a Total time is an estimate given the steps and times supplied on the protocol as well as information provided by the supplier. ^b Cost per sample does not include the cost of additional reagents required and not supplied by the kit, or DNA spike-ins to normalise result. It is calculated as a minimum taking into account the least amount of sample/reagents required as well as using the kits that allow for the maximum samples (50 samples for most kits). In cases where more sample is required the price can be as much as 3× higher per sample than the one displayed in the table.



From Table 1, the average time required by kits for miRNA extraction was 52 min with the average number of steps being ~ 17 and average cost per sample of $\sim \pounds 9.47$ (minimum based on kits for many samples). One of the kits (miRNeasy) involved phenol-chloroform extraction which has now been updated (miRNeasy Advanced) and no longer necessitates the use of such chemicals. Another extraction strategy that bypasses the need for phenol-chloroform extraction is that used by MagMAX mirVana total RNA isolation kit (Applied Biosystems) and Taqman miRNA ABC purification kit (ThermoFisher). Both kits use magnetic beads coated with oligonucleotides to selectively isolate broad panels of miRNAs. Such kits have technical limitations including their reliance on costly equipment (especially in the case of MagMAX), a rather limited capturing efficiency limited to the extraction of only currently known miRNA sequences. It is worth noting however that all kits require the use of guanidinium thiocyanate for the extraction step irrespective of sample type. This chaotropic salt is involved in the breakdown of extracellular vesicles and proteins to allow miRNA release.

Previous reports have also shown that there is a lot of variability between the kits and miRNA is not always reliably extracted despite the use of spike-in controls.^{32,33} In the absence of a standardised protocol used by all labs, specific studies may be influenced by the miRNA isolation method used, making comparisons between studies challenging, if not impossible.³⁴ There have also been reports that using these kits might result in partial loss of miRNAs with low GC content.³⁵ When directly compared to each other, there does not appear to be a single most effective kit for miRNA isolation and the selection of kits generally is dictated by the type of sample and convenience.³⁶ Finally, steps to automate extraction using the such kits have been made using a bench-top device which however would bring up the cost by thousands of pounds, making it an inaccessible option for most.

However, the main limitation of such kits is the variability and lack of reliability introduced through sample loss during the extraction process. This means that even if the kits were to be automated, unless the detection method was able to normalise the results using an internal control, the kits are limited by their lack of consistency.

Advances

Protocol optimisation. General principles used by kits such as solid-phase extraction could be miniaturised and implemented in POC devices. Some recent advances involve improved protocols such as the one devised by Lekchnov *et al.* to improve speed and efficiency of miRNA isolation harnessing the utility of octanoic acid to form insoluble complexes with plasma proteins and guanidinium to break down proteins and vesicles to release miRNAs.^{37,38} Others have also suggested improvements to current extraction protocols through addition of yeast transfer RNA and glycogen or incorporating magnetic nanoparticles with protein corona.^{39,40}

Novel off-chip isolation methods. Others have devised new techniques such as Jimenez *et al.* who demonstrated the usefulness of titanium dioxide nanofibers to extract miRNAs from cells and serum (Fig. 2). This takes advantage of the interaction between titanium and the phosphate groups of nucleic acids. Through optimizing binding and elution conditions, the proposed method improved miRNA recovery by 4.2-fold compared with the best performing control (silica fibres).⁴¹ Khan *et al.* reported on the use of capillary electrophoresis. This method took advantage of proteins that selectively bind to different nucleic acids and assist in their separation. Detection of miRNAs was accomplished from serum using fluorescence in around 20 min. This however still requires an expensive capillary electrophoresis system and thus is far from an on-chip extraction method.⁴²



Fig. 2 Visual summary of the off-chip miRNA extraction methodologies explored in this review and the utilised samples to achieve this: A) polymer-based exosome entrapment,⁴⁵ B) PDMS functionalised with anti-CD-63 antibodies for exosome entrapment,⁴⁷ C) capillary electrophoresis,⁴² D) titanium dioxide nanofibers for miRNA isolation,⁴¹ E) advanced glass membrane column for EV entrapment,⁴⁶ F) single bead trapping array for exosome isolation (using anti-CD-63 antibodies), G) EpCAM aptamer-coated magnetic nanoparticles for exosome isolation.⁴⁴



Finally, some groups have focused more on miRNA extraction specifically from exosomes and developed ways of extracting exosomes for subsequent miRNA quantification. Tayebi *et al.* proposed a method of exosome purification using microfluidic hydrodynamic trapping through combining immunoaffinity to confine exosomes to polystyrene microbead surfaces, with passive trapping through microfluidic channels. The sample used was cell supernatant containing exosomes and phenol-chloroform extraction was used prior to miRNA detection by RT-qPCR.⁴³ Zhou *et al.* used $\text{Fe}_3\text{O}_4@\text{SiO}_2$ -aptamer nanoparticles to separate exosomes *via* magnetic separation in solution and demonstrated the utility of this method in both saliva and urine by subsequent detection on a lateral flow assay (LFA), later confirmed by RT-qPCR.⁴⁴ Grunt *et al.* proposed a method of exosome extraction involving a mannurite-gulonate polymer to entrap and enrich exosomes from plasma, serum, urine and cell samples. For miRNA release, chaotropic salts were added and although successful the overall process remained very labour-intensive.⁴⁵ Yukawa *et al.* took advantage of spinoidal decomposition to form a co-continuous structure to allow extracellular vesicle isolation in just 10 minutes.⁴⁶ However, for subsequent miRNA extraction, commercial kits were used underlining that although a step in the right direction, this again falls short of the requisites for an on-chip miRNA extraction kit. Kanwar *et al.* used a chip made of PDMS that was functionalised with antibodies against CD63 (commonly over-expressed on the surface of exosomes). This allowed on-chip capturing of exosomes from serum. The exosomes were then quantified on-chip but detection of miRNAs was achieved by RT-qPCR following miRNA extraction by extraction kits.⁴⁷

These recently developed techniques show a lot of promise and appear easier to translate into a POC device owing to their simplistic nature and incorporation of well-established techniques. They are, however, currently at an early stage of development and still require off-chip sample pre-processing.

Hybrid methods of miRNA extraction and detection

On-chip extraction with off-chip sample preparation

MiRNA extraction chips have been developed that still require steps such as cell lysis to be carried out off-chip before addition of the sample onto the device. This adds a step to the process which means that further optimisations are required for such devices to reach the market as a single-step POC device for miRNA extraction and sensing. As a result, they are here defined as hybrid methods (Fig. 3). An example of such a device combining both on-chip and off-chip elements is that developed by Zhong *et al.* This device was able to extract miRNAs, following off-chip cell lysis, to a standard identical to that of the Ambion Purelink miRNA isolation kit. This was carried out in 15 min on a PDMS microfluidic device through incorporating multiple microwells that contained buffers necessary for sample processing (*i.e.* RNA binding, washing and elution). The miRNAs were bound onto silica magnetic particles which were transferred between wells using a magnet. The final elution was prepared within 15 min and on-chip RT-PCR was carried out proving similar results to the extraction kit used for comparison while the process was both faster and cheaper.⁴⁸

Slouka *et al.* used electrophoresis as a sample pre-treatment method following cell lysis. This was then followed by concentration of the miRNAs using a cation exchange membrane.⁴⁹ Similarly, Schoch *et al.* used isotachopheresis with an incorporated sieving matrix to extract, isolate and preconcentrate small RNAs, including miRNAs, from cell lysates.⁵⁰ The methodologies included an off-chip cell lysis procedure which was based on lysis buffers and chloroform. Dame *et al.* reported the use thermo-electric cell lysis followed by on-chip gel electrophoresis for miRNA separation. When compared with the mirVana kit, their method reportedly allowed 100× higher yield/efficiency when comparing the final eluates by RT-qPCR detection.⁵¹ Wei *et al.* also harnessed the utility of microchip electrophoresis for miRNA filtering following off-chip cell lysis by




Fig. 3 Hybrid methods (off- and on-chip components) of miRNA extraction: A) acoustic waves and seeding particles for EV entrapment,⁵⁵ B) electrophoresis in buffer through nanofilter membrane,⁵⁷ C) thermo-electric cell lysis,^{51,58} D) electrophoretic miRNA purification,⁵⁸ E) isotachopheresis which involves the movement of a leading electrolyte (green) and a trailing electrolyte (blue),⁵⁰ F) magnetic particles for removal of larger nucleic acids in the process of miRNA isolation.⁴⁸



ultrasonication and centrifugation and achieved very high recoveries (94.9–108%).⁵² Although these electrophoretic methods seem promising, they still require manual handling at times and are thus not entirely on-chip extraction methods.

Qian *et al.* performed ultracentrifugation to isolate exosomes from either cell lysate or spiked into exosome-depleted serum, prior to adding the sample onto their device where they were enriched by an agarose fork-shaped microchannel through a passive capillary force. Following addition onto the device, the process of miRNA isolation including sensing *via* catalysed hairpin assembly took 10 minutes.⁵³ Although quick and capable of detecting exosomal miRNAs from serum, this method in its current state requires a fair amount of sample pre-processing prior to addition onto the device and thus necessitates further optimisation.

Another approach to miRNA extraction was that developed by Deng *et al.* This method involves a foldable, multi-layer paper chip to extract, purify and detect miRNAs following off-chip cell lysis. Although the process took 90 min, it demonstrated great promise in its ability to achieve multiplex miRNA analysis.⁵⁴

On-chip extraction with off-chip detection

On-chip miRNA extraction platforms have also been developed that required no off-chip pre-processing but were typically followed by off-chip miRNA detection (most typically *via* RT-qPCR). Although these extraction technologies may well be compatible with on-chip detection, this is yet to be demonstrated and they are also classified here as hybrid methods. An example of such a device is that developed by Ku *et al.* which incorporated acoustic trapping in an automated microfluidic platform for extracellular vesicle enrichment. Besides successfully enriching EVs, the miRNAs were subsequently extracted.⁵⁵ This method of EV isolation was also used later as part of a high-throughput screening to identify miRNA biomarkers for prostate cancer.⁵⁶

Lee *et al.* used electrophoresis to extract miRNAs from serum samples through a nanofilter membrane and demonstrated comparable miRNA Cq values using RT-qPCR to a commercially available miRNA extraction kit, with the

whole process of on-chip extraction lasting around 30 min.⁵⁷ Behrmann *et al.* incorporated thermoelectric lysis onto a microfluidic device in order to extract miRNAs directly from cells which was followed by gel electrophoresis to isolate them. When compared to the mirVana isolation kit (Ambion), the chip's performance was miRNA-dependent, performing 110–220 times better for miR-16 and 8.5–14 times better for let-7a (in terms of Ct values obtained). The chip was able to extract miRNAs successfully for detection by stem-loop RT-qPCR from as little as 5 cells.⁵⁸

On-chip miRNA extraction and detection

Incorporating all aspects of sample processing from miRNA extraction to amplification if necessary and finally sensing on the same platform has the potential to revolutionise the field of personalised medicine. Recently, there has been great progress on this front and unlike in the previous section where most technologies were primarily developed for extraction of cellular miRNAs, this section focuses mostly on on-chip extraction combined with on-chip detection of miRNAs from liquid biopsies, with several examples illustrated in Fig. 4. Such technologies have probably the greatest translational potential, with applications ranging from widespread public screening to longitudinal monitoring.

Tang *et al.* developed a new method of single-drop microextraction whereby the analyte is transferred into a small drop of extraction solvent. This was integrated into a magnetic three-phase single-drop microextraction which enabled release and subsequent detection of miRNAs through triggering the formation of hyperbranched DNA-iron oxide networks. When applied to the detection of miRNAs from serum samples, it allowed researchers to distinguish between samples from healthy volunteers and those from patients with hepatocellular carcinoma with only 6 seconds required for extraction and 5 minutes for detection.⁵⁹ Zhang *et al.* demonstrated the usefulness of microencapsulation in combination with a particle counter for digital analysis to detect miRNAs directly from plasma in less than 3 hours and down to 10 single copies of miRNA. The device was able to




Fig. 4 Visual summary of on-chip methods of miRNA extraction: A) miRNA encapsulated in microdroplets,⁶⁰ B) magnetic single-droplet extraction where the serum sample (yellow) form hyperbranched DNA-iron oxide networks into the organic phase (pink) as they are magnetically attracted to the extraction solvent (blue) held by a magnetic rod (grey),⁵⁹ C) magnetic beads coated in anti-CD-63 antibodies for exosome isolation,^{61,62} D) surface acoustic waves for extracellular vesicle lysis.⁶³





Table 2 Off-chip, hybrid and on-chip miRNA processing platforms discussed in the review. Abbreviations used in table: NA = not applicable, NR = not reported, NGS = next generation sequencing, RT-qPCR = reverse transcriptase quantitative polymerase chain reaction

Liquid biopsy or cells?	Biofluid/cell lysate	Disease targeted	Biofluid processing method for miRNA isolation	Control used (e.g. commercial kit)	Efficacy compared to control	Analysis/extraction time	Amplification required?	Sensing method	Ref.
Off-chip miRNA extraction									
Both	Serum and cell lysate	NA	TiO ₂ nanofibres	Silica columns, beads and fibres	4.2× better than the best performing control (silica fibres)	~20–25 min extraction	Yes	RT-qPCR	41
Liquid biopsy	Serum	Liver cancer	Protein-facilitated affinity capillary electrophoresis	NR	NA	20 min	No	Laser-induced fluorescence	42
Cells	Cell lysate	NR – stressed or not cells	Single-bead trapping arrays	NR	NA	NR	Yes	RT-qPCR	43
Both	Lung cells, urine and saliva	Lung cancer	Fe ₃ O ₄ @SiO ₂ -Aptamer nanoparticles	NR	NA	NR	Yes – duplex-specific nuclease	Fluorescence on LFAs	44
Liquid biopsy	Plasma and serum	NR	MGP-based polymer for exosome entrapment	Total exosome RNA and protein isolation kit (Invitrogen)	Higher reproducibility	NR	Yes	RT-qPCR	45
Liquid biopsy	Serum, urine and cells	NA	Advance glass membrane column (AGC) with macropores for EV isolation	ExoCap and ExoQuick	Higher number of distinct miRNAs detected using AGC than others	10 min for EV extraction	Yes	RT-qPCR	46
Liquid biopsy	Serum	Pancreatic cancer	PDMS functionalized with antibodies against CD63	NR	NA	NR	Yes	RT-qPCR/miRNA Openarray	47
Hybrid miRNA extraction and detection									
Liquid biopsy	Serum	Hepatocellular carcinoma	Electrophoresis through nanofilter membrane	miRNeasy serum/plasma kit (Qiagen)	Comparable Ct values	30 min for extraction	Yes	RT-qPCR	57
Liquid biopsy	Urine	NA	Acoustic trapping for EV enrichment	Ultracentrifugation	Higher miRNA reads	NR	Yes	NGS	55
Cells	Breast cancer cells	Breast cancer	Thermo-electric lysis of cells	mirVana kit (Ambion)	Comparable	NR (<5 min)	Yes	RT-qPCR	51
Cells	Cell lysate	Breast cancer	Thermo-electric lysis of cells + on-chip gel electrophoresis	mirVana kit (Life Tech.)	100× higher yield/efficiency	10 min extraction	Yes	RT-qPCR	58
Cells	Cell lysate	NA	Solid phase extraction by silica magnetic particles	PureLink™ miRNA isolation kit (Invitrogen)	Identical	15 min	Yes	On-chip RT-qPCR	48
Cells	Cell lysate	NA	Isotachopheresis after off-chip cell lysis	NR	NA	170 s ± 10%	NA – no specific miRNAs were detected	Epifluorescent microscope	50
Cells	Cell lysate	Cancer diagnostics (miRNAs for lung cancer)	Off-chip cell lysis. miRNAs captured on paper-based device	NR	NA	90 min (for the entire process)	Yes – HP-EXPAR	Quantum dots for optical sensing	54
Cells	Cell lysate	Bladder cancer	Off-chip cell lysis. Filtering of miRNA by microchip electrophoresis	NR	NA	NR (60 min incubation time)	No	Laser-induced fluorescence	52



Table 2 (continued)

Liquid biopsy or cells?	Biofluid/cell lysate	Disease targeted	Biofluid processing method for miRNA isolation	Control used (e.g. commercial kit)	Efficacy compared to control	Analysis/extraction time	Amplification required?	Sensing method	Ref.
Cells	Cell lysate	NR	Enrichment <i>via</i> agarose fork-shaped microchannel (after ultracentrifugation for exosome isolation)	NR	NA	10 min on chip (with preparation beforehand)	No	Catalysed hairpin assembly	53
Cells	Cell lysate	Head and neck squamous cell carcinoma	Chemical lysis and electrophoresis through agarose	NR	NA	30 min total (incl. 15 min for separation only)	No – preconcentration unit incorporated	Anion exchange membrane <i>via</i> surface inversion	49
On-chip miRNA extraction and detection									
Liquid biopsy	Serum	Hepatocellular carcinoma	Magnetic three-phase single-drop microextraction	NR – used spike in to monitor efficacy	NA	6 s for extraction and 5 min for detection	Yes – hyperbranched DNA/Fe ₃ O ₄ networks	Spectrophotometric detection	59
Both	Breast cancer cells and plasma	Cardiovascular disease	Magnetic beads coated with anti-CD63 for EV extraction	NR – calculated efficiency of extraction	NA	5 h (240 min EV extraction, 20 min for miRNA isolation and 5 min FET-based microRNA detection)	No	Field effect transistor	61
Liquid biopsy	Plasma	Breast cancer	Magnetic beads coated with anti-CD63 for EV extraction	NR	NA	NR	No	Field effect transistor	62
Liquid biopsy	Plasma	Colon cancer	miRNAs encapsulated in microdroplets	miRNeasy serum/plasma kit (Qiagen)	2–3 orders of magnitude lower LOD than RT-qPCR	3 h total	Yes – isothermal exponential amplification (EXPAR)	Fluorescence	60
Liquid biopsy	Plasma and serum	Cancer diagnostics (miRNAs for pancreatic/lung cancer)	Surface acoustic waves for EV lysis	miRNeasy serum/plasma kit (Qiagen), ExoQuick® (System Biosciences Inc.)	Comparable	30 min	No	Ion exchange membrane	63

detect miRNA with a limit of detection of about 50 copies per mL of plasma and was thus able to distinguish healthy donor samples from those originating from patients with metastatic colon cancer based on detection of Let-7a levels.⁶⁰

Cheng *et al.* and Huang *et al.* used anti-CD63 antibody coated magnetic beads to first bind to and then extract extracellular vesicles (EVs) from plasma.^{61,62} Cheng *et al.* incorporated the beads onto a microfluidic device and included a miRNA extraction component following EV extraction which involved EV lysis followed by capturing of the miRNAs of interest on magnetic beads coated with complementary DNA and allowed for detection down to 1 fM concentrations of miRNA using a field-effective-transistor (FET). A pneumatic-driven microfluidic device allowed automation of the aforementioned steps into an all-encompassing device for the detection of cardiovascular disease-specific miRNAs.⁶¹ Huang *et al.* used the same method of extraction and detection and demonstrated the utility of the device in breast cancer diagnosis.⁶²

Ramshani *et al.* used an integrated microfluidic device to detect both free-floating and EV-specific miRNAs directly from plasma in 30 min. This was achieved using surface acoustic waves (SAW) to break down the EVs.⁶³ It was previously shown that these waves, generated by electrodes, are capable of lysing both cells and exosomes to release incorporated nucleic acids.^{64,65} Following this lysis step, the miRNAs were concentrated using cation-exchange membranes and detected using anion-exchange membranes. To detect free-floating miRNAs, the same procedure was followed while the SAW-producing component was switched off. The device was able to generate similar results to conventional methods of extraction and detection by RT-qPCR in a fraction of the time and in a processing-free manner.⁶³

Finally, certain sensing technologies have been developed that do not necessitate any sample pre-processing and allow detection of miRNAs directly in un-processed samples. Bypassing sample pre-processing often requires sensing technologies that are both ultrasensitive (most typically with single molecule resolution) and highly specific, to detect the miRNA of interest in complex biological matrices. The absence of processing, however, may also mean that only free-circulating miRNAs can be detected, exosomal miRNAs or miRNAs involved in protein complexes being out of reach.

Cai *et al.* were able to detect miRNAs from the serum of prostate cancer patients using electro-optical nanopore sensing. The technology was sensitive and specific enough to distinguish patients with active disease from those in remission through multiplex miRNA profiling.⁶⁶ Tavallaie *et al.* used gold-coated magnetic nanoparticles (Au@MNP) and electric-field-induced assembly of the DNA-Au@MNP network to detect microRNAs directly in blood in around 30 min. This allowed for detection of miRNAs from 10 aM–1 nM (in line with RT-qPCR) and was able to detect small differences in miRNA levels within blood samples obtained from mice with growing tumours.⁶⁷ Kangkamano *et al.* used

pyrrolidinyl PNA polypyrrole/silver nanofoam electrodes for electrochemical miRNA sensing. This allowed for detection of miRNA directly from plasma in the range of 0.2 fM–1 nM with a hybridisation time of 5 min,⁶⁸ which is a lot faster than other similar label-free electrochemical miRNA biosensors reported.^{69–77} McArdle *et al.* used electrocatalytic platinum nanoparticles to detect miRNAs directly from human plasma and CSF on a centrifugal microfluidic device. This device was able to detect differences in miR-134 expression levels between control samples from healthy volunteers and those obtained from patients with refractory epilepsy or non-epileptic patients who experienced status epilepticus.⁷⁸

Conclusions and perspectives

We have herein summarised some of the most promising methodologies and technologies for miRNA isolation developed in the last decade. All of them have demonstrated either incremental or more significant potential for simplifying complex miRNA extraction. Some appear more easily translatable into a POC device than others because of their simplicity, automation and amenity to miniaturisation. This has already led to all-in-one device prototypes capable of detecting miRNAs either directly from biological matrices or through various processing or extraction steps performed within the device itself.^{59–63} Such technologies could pave the way to the next generation of point-of-care nucleic acid tests with applications ranging from widespread public screening to personalised medicine. But importantly, they could also become very powerful tools to identify new miRNA biomarkers. The relative absence on the current market of diagnostic tests based on miRNAs detection from liquid biopsies can be explained by the challenges faced by researchers to identify and clinically validate miRNAs. As explained throughout this review, miRNA analysis is very strongly influenced by the way they are extracted, stored, and detected. Lifting this technical limitation should see the emergence of more clinically validated miRNAs and the demand for miRNA POC device flourish.

All technologies mentioned in this review provide to some extent an alternative to the current costly, time-consuming and elaborate miRNA extraction kits (Table 2). They are also new tools made available to researchers to better understand the life cycle of miRNAs in bodily fluids. Fundamental questions such as miRNA compartmentalisation or protein complexation are critical to help develop new diagnostic or prognostic tests that are fit for purpose. For example, methodologies allow for isolation of miRNAs specifically from EVs^{43,46,47,53,55,59,61–63} while others are less selective toward the source of miRNAs, opening doors to both EV-specific and total miRNA biomarkers. Other technologies sensitive enough to detect miRNAs directly from bodily fluids will however be targeting a different pool of biomarkers, those miRNAs that are freely circulating. Some recurrent approaches used electrophoretic methods for miRNA isolation/purification,^{49–52,57} beads for extracellular vesicle



isolation based on surface functionalisation^{43,61,62} as well as acoustic waves for either EV lysis⁶³ or EV entrapment.⁵⁵

Which technology has the greatest potential is a question that cannot yet be answered with our current knowledge. But it is clear that a diversity of approaches and platforms is needed to improve our understanding of circulating cell-free miRNAs and develop new tests to detect them, at the POC or in research facilities. Whilst this review focused primarily on sample processing and miRNA extraction, how much processing and pre-purification is required in a POC nucleic acid will also be dictated by the nature of the chosen detection methodology. When ultrapure miRNA extracts are typically needed for most PCR-based tests, new on-chip miRNA sensing technologies are also being developed that are increasingly compatible with complex biological matrices and would therefore require less stringent processing prior to analysis. Processing and detection are strongly connected and only the best combinations will stand a chance to be implemented in clinical practise, providing novel routes to early diagnose as well as providing insights for better clinical management. With specific miRNA deregulation being associated with an increasingly large number of medical conditions including most cancer types, cardiovascular diseases, neurological disorders and infectious diseases,^{1–3} the need for new nucleic acid tests has never been more urgent.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors thank the March of Dimes for financial support.

Notes and references

- 1 N. Rosenfeld, R. Aharonov, E. Meiri, S. Rosenwald, Y. Spector, M. Zepeniuk, H. Benjamin, N. Shabes, S. Tabak, A. Levy, D. Lebanony, Y. Goren, E. Silberschein, N. Targan, A. Ben-Ari, S. Gilad, N. Sion-Vardy, A. Tobar, M. Feinmesser, O. Kharenko, O. Nativ, D. Nass, M. Perelman, A. Yosepovich, B. Shalmon, S. Polak-Charcon, E. Fridman, A. Avniel, I. Bentwich, Z. Bentwich, D. Cohen, A. Chajut and I. Barshack, MicroRNAs accurately identify cancer tissue origin, *Nat. Biotechnol.*, 2008, **26**(4), 462–469.
- 2 J. Wang, J. Chen and S. Sen, MicroRNA as Biomarkers and Diagnostics, *J. Cell. Physiol.*, 2016, **231**(1), 25–30.
- 3 V. Kaul, K. I. Weinberg, S. D. Boyd, D. Bernstein, C. O. Esquivel, O. M. Martinez and S. M. Krams, Dynamics of Viral and Host Immune Cell MicroRNA Expression during Acute Infectious Mononucleosis, *Front. Microbiol.*, 2018, **8**, 2666.
- 4 R. Yi, Y. Qin, I. G. Macara and B. R. Cullen, Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs, *Genes Dev.*, 2003, **17**(24), 3011–3016.
- 5 Y. Lee, C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Rådmark, S. Kim and V. N. Kim, The nuclear RNase III Drosha initiates microRNA processing, *Nature*, 2003, **425**(6956), 415–419.
- 6 J. Höck and G. Meister, The Argonaute protein family, *Genome Biol.*, 2008, **9**(2), 210–210.
- 7 R. W. Carthew and E. J. Sontheimer, Origins and Mechanisms of miRNAs and siRNAs, *Cell*, 2009, **136**(4), 642–655.
- 8 T. P. Chendrimada, K. J. Finn, X. Ji, D. Baillat, R. I. Gregory, S. A. Liebhaber, A. E. Pasquinelli and R. Shiekhattar, MicroRNA silencing through RISC recruitment of eIF6, *Nature*, 2007, **447**(7146), 823–828.
- 9 L. Xu, B. F. Yang and J. Ai, MicroRNA transport: a new way in cell communication, *J. Cell. Physiol.*, 2013, **228**(8), 1713–1719.
- 10 C. Villarroja-Beltri, C. Gutiérrez-Vázquez, F. Sánchez-Cabo, D. Pérez-Hernández, J. Vázquez, N. Martín-Cofreces, D. J. Martínez-Herrera, A. Pascual-Montano, M. Mittelbrunn and F. Sánchez-Madrid, Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs, *Nat. Commun.*, 2013, **4**(1), 2980.
- 11 P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogoseva-Agadjanyan, A. Peterson, J. Noteboom, K. C. Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari, Circulating microRNAs as stable blood-based markers for cancer detection, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**(30), 10513.
- 12 A. Aryani and B. Denecke, In vitro application of ribonucleases: comparison of the effects on mRNA and miRNA stability, *BMC Res. Notes*, 2015, **8**(1), 164.
- 13 C. W. Price, D. C. Leslie and J. P. Landers, Nucleic acid extraction techniques and application to the microchip, *Lab Chip*, 2009, **9**(17), 2484–2494.
- 14 N. Ali, R. D. C. P. Rampazzo, A. D. T. Costa and M. A. Krieger, Current Nucleic Acid Extraction Methods and Their Implications to Point-of-Care Diagnostics, *BioMed Res. Int.*, 2017, **2017**, 9306564.
- 15 S. Inamdar, R. Nitiyanandan and K. Rege, Emerging applications of exosomes in cancer therapeutics and diagnostics, *Bioeng. Transl. Med.*, 2017, **2**(1), 70–80.
- 16 M. Ilić and P. Hofman, Pros: Can tissue biopsy be replaced by liquid biopsy?, *Transl. Lung Cancer Res.*, 2016, **5**(4), 420.
- 17 C. Alix-Panabières and K. Pantel, Liquid biopsy: from discovery to clinical application, *Cancer Discovery*, 2021, **11**(4), 858–873.
- 18 T.-R. Li, X.-N. Wang, C. Sheng, Y.-X. Li, F. Z.-T. Li, Y. Sun and Y. Han, Extracellular vesicles as an emerging tool for the early detection of Alzheimer's disease, *Mech. Ageing Dev.*, 2019, **184**, 111175.
- 19 G. Siravegna, S. Marsoni, S. Siena and A. Bardelli, Integrating liquid biopsies into the management of cancer, *Nat. Rev. Clin. Oncol.*, 2017, **14**(9), 531–548.
- 20 M. El-Mogy, B. Lam, T. A. Haj-Ahmad, S. McGowan, D. Yu, L. Nosal, N. Rghei, P. Roberts and Y. Haj-Ahmad, Diversity and



- signature of small RNA in different bodily fluids using next generation sequencing, *BMC Genomics*, 2018, **19**(1), 408.
- 21 J. A. Weber, D. H. Baxter, S. Zhang, D. Y. Huang, K. How Huang, M. Jen Lee, D. J. Galas and K. Wang, The MicroRNA Spectrum in 12 Body Fluids, *Clin. Chem.*, 2010, **56**(11), 1733–1741.
 - 22 E. K. Hanson, H. Lubenow and J. Ballantyne, Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs, *Anal. Biochem.*, 2009, **387**(2), 303–314.
 - 23 K. Wang, Y. Yuan, J.-H. Cho, S. McClarty, D. Baxter and D. J. Galas, Comparing the MicroRNA spectrum between serum and plasma, *PLoS One*, 2012, **7**, e41561.
 - 24 J. D. Arroyo, J. R. Chevillet, E. M. Kroh, I. K. Ruf, C. C. Pritchard, D. F. Gibson, P. S. Mitchell, C. F. Bennett, E. L. Pogosova-Agadjanyan, D. L. Stirewalt, J. F. Tait and M. Tewari, Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**(12), 5003.
 - 25 A. Turchinovich, L. Weiz, A. Langheinz and B. Burwinkel, Characterization of extracellular circulating microRNA, *Nucleic Acids Res.*, 2011, **39**(16), 7223–7233.
 - 26 A. Gallo, M. Tandon, I. Alevizos and G. G. Illei, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, *PLoS One*, 2012, **7**(3), e30679.
 - 27 C. C. Pritchard, H. H. Cheng and M. Tewari, MicroRNA profiling: approaches and considerations, *Nat. Rev. Genet.*, 2012, **13**(5), 358–369.
 - 28 M. Accerbi, S. A. Schmidt, E. De Paoli, S. Park, D. H. Jeong and P. J. Green, Methods for isolation of total RNA to recover miRNAs and other small RNAs from diverse species, *Methods Mol. Biol.*, 2010, **592**, 31–50.
 - 29 S. C. Tan and B. C. Yiap, DNA, RNA, and protein extraction: the past and the present, *J. Biomed. Biotechnol.*, 2009, **2009**, 574398.
 - 30 K. A. Melzak, C. S. Sherwood, R. F. B. Turner and C. A. Haynes, Driving Forces for DNA Adsorption to Silica in Perchlorate Solutions, *J. Colloid Interface Sci.*, 1996, **181**(2), 635–644.
 - 31 P. M. Godoy, N. R. Bhakta, A. J. Barczak, H. Cakmak, S. Fisher, T. C. MacKenzie, T. Patel, R. W. Price, J. F. Smith, P. G. Woodruff and D. J. Erle, Large Differences in Small RNA Composition Between Human Biofluids, *Cell Rep.*, 2018, **25**(5), 1346–1358.
 - 32 R. A. M. Brown, M. R. Epis, J. L. Horsham, T. D. Kabir, K. L. Richardson and P. J. Leedman, Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal, *BMC Biotechnol.*, 2018, **18**(1), 16.
 - 33 A. Brunet-Vega, C. Pericay, M. E. Quílez, M. J. Ramírez-Lázaro, X. Calvet and S. Lario, Variability in microRNA recovery from plasma: Comparison of five commercial kits, *Anal. Biochem.*, 2015, **488**, 28–35.
 - 34 A. Podolska, B. Kaczkowski, T. Litman, M. Fredholm and S. Cirera, How the RNA isolation method can affect microRNA microarray results, *Acta Biochim. Pol.*, 2011, **58**(4), 535–540.
 - 35 Y.-K. Kim, J. Yeo, B. Kim, M. Ha and V. N. Kim, Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells, *Mol. Cell*, 2012, **46**(6), 893–895.
 - 36 O. Bryzgunova, M. Konoshenko, I. Zaporozhchenko, A. Yakovlev and P. Laktionov, Isolation of Cell-Free miRNA from Biological Fluids: Influencing Factors and Methods, *Diagnostics*, 2021, **11**(5), 865.
 - 37 E. A. Lekchnov, I. A. Zaporozhchenko, E. S. Morozkin, O. E. Bryzgunova, V. V. Vlassov and P. P. Laktionov, Protocol for miRNA isolation from biofluids, *Anal. Biochem.*, 2016, **499**, 78–84.
 - 38 A. Chanutin and R. R. Curnish, The precipitation of plasma proteins by short-chain fatty acids, *Arch. Biochem. Biophys.*, 1960, **89**(2), 218–220.
 - 39 E. Ban, D.-K. Chae, Y. S. Yoo and E. J. Song, An improvement of miRNA extraction efficiency in human plasma, *Anal. Bioanal. Chem.*, 2017, **409**(27), 6397–6404.
 - 40 S. Xu, S. Hossaini Nasr, D. Chen, X. Zhang, L. Sun, X. Huang and C. Qian, MiRNA Extraction from Cell-Free Biofluid Using Protein Corona Formed around Carboxyl Magnetic Nanoparticles, *ACS Biomater. Sci. Eng.*, 2018, **4**(2), 654–662.
 - 41 L. A. Jimenez, M. A. Gionet-Gonzales, S. Sedano, J. G. Carballo, Y. Mendez and W. Zhong, Extraction of microRNAs from biological matrices with titanium dioxide nanofibers, *Anal. Bioanal. Chem.*, 2018, **410**(3), 1053–1060.
 - 42 N. Khan, J. Cheng, J. P. Pezacki and M. V. Berezovski, Quantitative Analysis of MicroRNA in Blood Serum with Protein-Facilitated Affinity Capillary Electrophoresis, *Anal. Chem.*, 2011, **83**(16), 6196–6201.
 - 43 M. Tayebi, Y. Zhou, P. Tripathi, R. Chandramohanadas and Y. Ai, Exosome Purification and Analysis Using a Facile Microfluidic Hydrodynamic Trapping Device, *Anal. Chem.*, 2020, **92**(15), 10733–10742.
 - 44 P. Zhou, F. Lu, J. Wang, K. Wang, B. Liu, N. Li and B. Tang, A portable point-of-care testing system to diagnose lung cancer through the detection of exosomal miRNA in urine and saliva, *Chem. Commun.*, 2020, **56**(63), 8968–8971.
 - 45 M. Grunt, A. V. Failla, I. Stevic, T. Hillebrand and H. Schwarzenbach, A novel assay for exosomal and cell-free miRNA isolation and quantification, *RNA Biol.*, 2020, **17**(4), 425–440.
 - 46 H. Yukawa, S. Yamazaki, K. Aoki, K. Muto, N. Kihara, K. Sato, D. Onoshima, T. Ochiya, Y. Tanaka and Y. Baba, Co-continuous structural effect of size-controlled macro-porous glass membrane on extracellular vesicle collection for the analysis of miRNA, *Sci. Rep.*, 2021, **11**(1), 8672.
 - 47 S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Negrath, Microfluidic device(ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes, *Lab Chip*, 2014, **14**(11), 1891–1900.
 - 48 R. Zhong, K. Flack and W. Zhong, Automatic extraction and processing of small RNAs on a multi-well/multi-channel(M&M) chip, *Analyst*, 2012, **137**(23), 5546–5552.
 - 49 Z. Slouka, S. Senapati, S. Shah, R. Lawler, Z. Shi, M. S. Stack and H.-C. Chang, Integrated, DC voltage-driven nucleic acid



- diagnostic platform for real sample analysis: Detection of oral cancer, *Talanta*, 2015, **145**, 35–42.
- 50 R. B. Schoch, M. Ronaghi and J. G. Santiago, Rapid and selective extraction, isolation, preconcentration, and quantitation of small RNAs from cell lysate using on-chip isotachopheresis, *Lab Chip*, 2009, **9**(15), 2145–2152.
 - 51 G. Dame, J. Lampe, S. Hakenberg and G. Urban, Development of a Fast miRNA Extraction System for Tumor Analysis Based on a Simple Lab on Chip Approach, *Procedia Eng.*, 2015, **120**, 158–162.
 - 52 K. Wei, J. Zhao, X. Luo, S. Qiu, F. He, S. Li and S. Zhao, An ultrasensitive microchip electrophoresis assay based on separation-assisted double cycling signal amplification strategy for microRNA detection in cell lysate, *Analyst*, 2018, **143**(6), 1468–1474.
 - 53 C. Qian, Y. Xiao, J. Wang, Y. Li, S. Li, B. Wei, W. Du, X. Feng, P. Chen and B.-F. Liu, Rapid exosomes concentration and in situ detection of exosomal microRNA on agarose-based microfluidic chip, *Sens. Actuators, B*, 2021, **333**, 129559.
 - 54 H. Deng, X. Zhou, Q. Liu, B. Li, H. Liu, R. Huang and D. Xing, Paperfluidic chip device for small RNA extraction, amplification, and multiplexed analysis, *ACS Appl. Mater. Interfaces*, 2017, **9**(47), 41151–41158.
 - 55 A. Ku, N. Ravi, M. Yang, M. Evander, T. Laurell, H. Lilja and Y. Ceder, A urinary extracellular vesicle microRNA biomarker discovery pipeline; from automated extracellular vesicle enrichment by acoustic trapping to microRNA sequencing, *PLoS One*, 2019, **14**(5), e0217507.
 - 56 A. Ku, J. Fredsøe, K. D. Sørensen, M. Borre, M. Evander, T. Laurell, H. Lilja and Y. Ceder, High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer, *Front. Oncol.*, 2021, **11**(386), 631021.
 - 57 K. Lee, J.-H. Kang, H.-M. Kim, J. Ahn, H. Lim, J. Lee, W.-J. Jeon, J.-H. Lee and K.-B. Kim, Direct electrophoretic microRNA preparation from clinical samples using nanofilter membrane, *Nano Convergence*, 2020, **7**(1), 1.
 - 58 O. Behrmann, M. Hügler, P. Bronsert, B. Herde, J. Heni, M. Schramm, F. T. Hufert, G. A. Urban and G. Dame, A lab-on-a-chip for rapid miRNA extraction, *PLoS One*, 2019, **14**(12), e0226571.
 - 59 S. Tang, T. Qi, Y. Yao, L. Tang, W. Chen, T. Chen, W. Shen, D. Kong, H.-W. Shi and T. Liu, Magnetic Three-Phase Single-Drop Microextraction for Rapid Amplification of the Signals of DNA and MicroRNA Analysis, *Anal. Chem.*, 2020, **92**(18), 12290–12296.
 - 60 K. Zhang, D.-K. Kang, M. M. Ali, L. Liu, L. Labanieh, M. Lu, H. Riazifar, T. N. Nguyen, J. A. Zell and M. A. Digman, Digital quantification of miRNA directly in plasma using integrated comprehensive droplet digital detection, *Lab Chip*, 2015, **15**(21), 4217–4226.
 - 61 H.-L. Cheng, C.-Y. Fu, W.-C. Kuo, Y.-W. Chen, Y.-S. Chen, Y.-M. Lee, K.-H. Li, C. Chen, H.-P. Ma and P.-C. Huang, Detecting miRNA biomarkers from extracellular vesicles for cardiovascular disease with a microfluidic system, *Lab Chip*, 2018, **18**(19), 2917–2925.
 - 62 C. C. Huang, Y. H. Kuo, Y. S. Chen and G. B. Lee, An Integrated Microfluidic System for Early Diagnosis of Breast Cancer in Liquid Biopsy by Using MicroRNA and FET Biosensors, *2021 IEEE 34th International Conference on Micro Electro Mechanical Systems (MEMS)*, 2021, pp. 318–321.
 - 63 Z. Ramshani, C. Zhang, K. Richards, L. Chen, G. Xu, B. L. Stiles, R. Hill, S. Senapati, D. B. Go and H.-C. Chang, Extracellular vesicle microRNA quantification from plasma using an integrated microfluidic device, *Commun. Biol.*, 2019, **2**(1), 189.
 - 64 J. Reboud, Y. Bourquin, R. Wilson, G. S. Pall, M. Jiwaji, A. R. Pitt, A. Graham, A. P. Waters and J. M. Cooper, Shaping acoustic fields as a toolset for microfluidic manipulations in diagnostic technologies, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**(38), 15162–15167.
 - 65 D. Taller, K. Richards, Z. Slouka, S. Senapati, R. Hill, D. B. Go and H.-C. Chang, On-chip surface acoustic wave lysis and ion-exchange nanomembrane detection of exosomal RNA for pancreatic cancer study and diagnosis, *Lab Chip*, 2015, **15**(7), 1656–1666.
 - 66 S. Cai, T. Pataillot-Meakin, A. Shibakawa, R. Ren, C. L. Bevan, S. Ladame, A. P. Ivanov and J. B. Edel, Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum, *Nat. Commun.*, 2021, **12**(1), 3515.
 - 67 R. Tavallaie, J. McCarroll, M. Le Grand, N. Ariotti, W. Schuhmann, E. Bakker, R. D. Tilley, D. B. Hibbert, M. Kavallaris and J. J. Gooding, Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood, *Nat. Nanotechnol.*, 2018, **13**(11), 1066–1071.
 - 68 T. Kangkarnano, A. Numnuam, W. Limbut, P. Kanatharana, T. Vilaivan and P. Thavarungkul, Pyrrolidiny PNA polypyrrole/silver nanofoam electrode as a novel label-free electrochemical miRNA-21 biosensor, *Biosens. Bioelectron.*, 2008, **102**, 217–225.
 - 69 L. Liu, Y. Chang, N. Xia, P. Peng, L. Zhang, M. Jiang, J. Zhang and L. Liu, Simple, sensitive and label-free electrochemical detection of microRNAs based on the in situ formation of silver nanoparticles aggregates for signal amplification, *Biosens. Bioelectron.*, 2017, **94**, 235–242.
 - 70 H.-A. Rafiee-Pour, M. Behpour and M. Keshavarz, A novel label-free electrochemical miRNA biosensor using methylene blue as redox indicator: application to breast cancer biomarker miRNA-21, *Biosens. Bioelectron.*, 2016, **77**, 202–207.
 - 71 L. Liu, N. Xia, H. Liu, X. Kang, X. Liu, C. Xue and X. He, Highly sensitive and label-free electrochemical detection of microRNAs based on triple signal amplification of multifunctional gold nanoparticles, enzymes and redox-cycling reaction, *Biosens. Bioelectron.*, 2014, **53**, 399–405.
 - 72 N. Xia, L. Zhang, G. Wang, Q. Feng and L. Liu, Label-free and sensitive strategy for microRNAs detection based on the formation of boronate ester bonds and the dual-



- amplification of gold nanoparticles, *Biosens. Bioelectron.*, 2013, **47**, 461–466.
- 73 J. Mandli, H. Mohammadi and A. Amine, Electrochemical DNA sandwich biosensor based on enzyme amplified microRNA-21 detection and gold nanoparticles, *Bioelectrochemistry*, 2017, **116**, 17–23.
 - 74 H.-L. Shuai, K.-J. Huang, W.-J. Zhang, X. Cao and M.-P. Jia, Sandwich-type microRNA biosensor based on magnesium oxide nanoflower and graphene oxide-gold nanoparticles hybrids coupling with enzyme signal amplification, *Sens. Actuators, B*, 2017, **243**, 403–411.
 - 75 N. Xia, Y. Zhang, X. Wei, Y. Huang and L. Liu, An electrochemical microRNAs biosensor with the signal amplification of alkaline phosphatase and electrochemical-chemical-chemical redox cycling, *Anal. Chim. Acta*, 2015, **878**, 95–101.
 - 76 Y. Zhou, Z. Zhang, Z. Xu, H. Yin and S. Ai, MicroRNA-21 detection based on molecular switching by amperometry, *New J. Chem.*, 2012, **36**(10), 1985–1991.
 - 77 H. Yin, Y. Zhou, H. Zhang, X. Meng and S. Ai, Electrochemical determination of microRNA-21 based on graphene, LNA integrated molecular beacon, AuNPs and biotin multifunctional bio bar codes and enzymatic assay system, *Biosens. Bioelectron.*, 2012, **33**(1), 247–253.
 - 78 H. McArdle, E. M. Jimenez-Mateos, R. Raoof, E. Carthy, D. Boyle, H. ElNaggar, N. Delanty, H. Hamer, M. Dogan, T. Huchtemann, P. Körtvelyessy, F. Rosenow, R. J. Forster, D. C. Henshall and E. Spain, “TORNADO” – Theranostic One-Step RNA Detector; microfluidic disc for the direct detection of microRNA-134 in plasma and cerebrospinal fluid, *Sci. Rep.*, 2017, **7**(1), 1750.

